瑞舒伐他汀对高血压患者血糖、血脂及超敏C反应蛋白水平的影响

目的探讨瑞舒伐他汀对高血压患者血糖、血脂及超敏C反应蛋白(hs-CRP)水平的影响。方法选择86例不伴有糖尿病的高血压患者,采用自身对照方法,在常规降压治疗的基础上加服瑞舒伐他汀。观察用药前及用药8周后空腹血糖(FBG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及hs-CRP的变化。结果本组患者治疗后TC、LDL-C及hs-CRP水平均较治疗前显著下降,而HDL-C水平却显著升高,治疗前后比较差异均有统计学意义(P<0.05或P<0.01);本组患者治疗后FBG及HbA1c水平较治疗前略有所上升,但治疗前后比较差异无统计学意义(P>0.05)。结论对高血压合并高脂血症及高hs-CRP水平者加用瑞舒伐他汀,可显著降低TC、LDL-C及hs-CRP水平,升高HDL-C水平,降低心血管临床终点。

Effects of rosuvastatin on the levels of blood glucose, blood lipid and hypersensitive C-reactive protein in patients with hypertension

Objective To investigate the effects of rosuvastatin on the levels of blood glucose,blood lipid and hypersensitive CA1.reactive protein(hsA1.CRP) in patients with hypertension.Methods According to selfA1.controlled method,86 selected hypertensive patients without diabetes received rosuvastatin in addition to the conventional treatment of decreasing blood pressure.The changes of fasting blood glucose(FBG),hemoglobin A1c(HbA1c),total cholesterol(TC),low density lipoprotein cholesterol(LDLA1.C),high density lipoprotein cholesterol(LDLA1.C) and hsA1.CRP were observed before administration of rosuvastatin and 8 weeks after administration.Results The levels of TC,LDLA1.C and hsA1.CRP in patients after treatment significantly decreased compared with before treatment,whereas the level of HDLA1.C markedly increased,and the statistical significance was presented comparing those before treatment with those after treatment.The levels of FBG and HbA1c in patients after treatment slightly increased compared with before treatment,but the difference showed no statistical difference.Conclusion The additive administration of rosuvastatin to patients with hypertension combined with hyperlipidaemia and highA1.level hsA1.CRP can notably decrease the levels of TC,LDLA1.C and hsA1.CRP,increase the level of HDLA1.C and reduce cardiovascular clinical endpoints.